がん臨床研究事業事前評価委員名簿
（○：委員長）
| 上西 紀夫 | 公立昭和病院 院長 |
| 消化器外科 | |
| Kaminishi M, Takubo K, Mafune K eds. The Diversity of Gastric Carcinoma. Springer-Verlag, Tokyo, 2005 | |
| Yoshizawa Nao, Yamaguchi H, Nomura S, Takenaka Y, Tsukamoto T, Tatematsu M, Goldenring JR, Kaminishi M. Emergence of Spasmolytic Polypeptide-Expressing Metaplasia (SPEM) in Mongolian Gerbils infected with Helicobacter pylori. Laboratory Investigation 87: 1265-1276, 2007 | |
| Mori K, Suzuki T, Uozaki H, Nakanishi H, Ueda T, Matsuno Y, Kodera Y, Sakamoto H, Yamamoto N, Sasako M, Kaminishi M, Sasaki H. Detection of minimal gastric cancer cells in peritoneal washings by focused microarray analysis with multiple markers: Clinical implications. Annals of Surgical Oncology 14: 1694-1702,2007 | |
○
| 土屋 了介 | 国立がんセンター中央病院・病院長 |
| 胸部外科学 特に進行肺がんの手術・集学的治療・周術期管理、胸部診断学 | |
| Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases. Nagai K, Sohara Y, Tsuchiya R, Goya T, Miyaoka E. Journal of Thoracic Oncology.2007 2-4 April:282-286 | |
| Immunohistochemical detection of GLUT-1 can discriminate between reactive masothelium and malignant mesothelioma. Kato Y, Tsuta K, Seki K, Miyagi A, Maeshima M A, Watanabe S,Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Modern Pathology. 2007 20:215-220 |
|
| Low-dose CT screening for lung cancer with automatic exposure control:phantom study. Gomi S, Muramatsu Y, Tsukagoshi S,Suzuki M, Kakinuma R, Tsuchiyua R, Moriyama N. Radiol Phys Technol. 2008 1:244-250 |
|
| 鳶巣 賢一 | 静岡県立静岡がんセンター 病院長 |
| 泌尿器科腫瘍の診断と治療 | |
| Transitional cell carcinoma of the urethra in men following cystectomy for bladder: multivariate analysis for risk factors. Tobisu K, Tanak Y, Mizutani T, Kakizoe T. J Urol. 1991; 146:1551-1554. | |
| 「Urologic Surgery シリーズ１２： 膀胱の手術」鳶巣賢一他担当編集, メディカルビュー社, （2002）. | |
| Radical Cystectomy with Preservation of Urethra in Female Patients with Bladder Cancer and Bladder Reconstruction with Ileum (Video Sessions) Tobisu K, Coloby PJ, Fujimoto H, Mizutani, T, Kakizoe T, 87th American Urological Association 1992 Annual Meeting(Washington, D.C.) May 10-14, 1992 | |
| 光冨 徹哉 | 愛知県がんセンター中央病院副院長，胸部外科部長 |
| 呼吸器外科学，臨床腫瘍学，臨床分子生物学 | |
| Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients with Non-Small-Cell Lung Cancer With Postoperative Recurrence. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. J Clin Oncol, 23: 2513-20, 2005 | |
| Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. u, Yatabe Y: Cancer Sci 98:1817-24, 2007 | |
| Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. J. Thorac Oncol, 4: 22-9, 2009 | |
| 武藤 徹一郎 | （財）癌研究会有明病院 メディカルディレクター・名誉院長 |
| 消化管外科 | |
| The evolution of cancer of the colon and rectum. Muto T, Bassey HJR, Morson BC, Cancer, 1975, 36:2251-2270. |
|
| 大腸ポリープ・ポリポーシス 臨床と病理 武藤徹一郎,医学書院,(1993) | |
| What's on in colorectal cancer study - A 30 years experience of Japanese Society for Cancer of the Colon and Rectum Presidential Address of The 21th Congress of The International Society of University Colon and Rectal Surgeons. Muto T, Istanbul 6.2006 | |
| 吉田 茂昭 | 青森県病院事業管理者（県立中央病院長） |
| 臨床腫瘍学 | |
| Yoshida S, Miyata Y, Ohtsu A, et al: Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 3: 128-33, 2000. | |
| 吉田茂昭：臨床医学の展望 癌の化学療法（内科的）.日本醫事新報4272：13-28,2006. | |
| Yoshida S. 17 Endoscopic treatment, In: Gastric Cancer (eds. Sugimura T, Sasako M) pp252-62, Oxford University Press (New York) 1997 | |
| 佐々木 康綱 | 埼玉医科大学内科学腫瘍内科教授 |
| がん薬物療法 | |
| Wataru Ichikawa, Kazuhiro Araki, ,Ken-ichi Fujita, Wataru Yamamoto, Hisashi Endo, Fumio Nagashima, Ryuhei Tanaka, Toshimichi Miya, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Yuichi Ando, Yuko Akiyama, Kaori Kawara, Yasutsuna Sasaki UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters. J. Natl. Cancer Inst. 100:224-225,2008 | |
| Ken-ichi Fujita, Wataru Yamamoto, Shoji Endo, Hisashi Endo, Fumio Nagashima, Wataru Ichikawa, Ryuhei Tanaka, Toshimichi Miya, Kazuhiro Araki, Keiji Kodama, Yu Sunakawa , Masaru Narabayashi, Keisuke Miwa, Yuichi Ando, Yuko Akiyama, Kaori Kawara, Tetsuya Kamataki and Yasutsuna Sasaki CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxypyridine are determinants of the respective variability of the pharmacokinetics of tegafur and 5-fluorouracil in Japanese patients with cancer given S-1 Cancer Sci. 99: 1049-1054,2008 | |
| Y. Akiyama, K. Fujita, F. Nagashima, W. Yamamoto, H. Endo, Y. Sunakawa, K. Yamashita, H. Ishida, K. Mizuno, K. Araki, W. Ichikawa, T. Miya, M. Narabayashi, K. Kawara, M. Sugiyama, T. Hirose, Y. Ando, and Y. Sasaki. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 2008 | |
